Etrasimod (APD334), an Oral, Next‐Generation Sphingosine‐1‐Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid‐Null Mice Injected with Colitogenic CD4+ T Cells

John Adams, Hussien Al‐Shamma(Beacon Clinical Research), Hongmei He(Arena Pharmaceuticals (United States)), Michelle Solomon(Beacon Clinical Research), Dominic P. Behan, Karin Lehmann‐Bruinsma(Beacon Clinical Research), Christopher J. Carroll(St George's, University of London)
The FASEB Journal
April 1, 2017
Cited by 2


Related Papers